TriangleDISEASE & TREATMENT SETTING
Lenvima: advanced Endometrial Carcinoma with MSI-H stated without a specific alteration, DMMR stated without a specific alteration after prior therapy
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
In combination with pembrolizumab for advanced endometrial carcinoma not MSI-H or dMMR, with progression following systemic therapy and not candidates for curative surgery or radiation
Broader topic: Endometrial Cancer
- Source population
- Not part of this definition
- Disease extent
- advanced
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- gene
- MSI-H
- alteration
- stated without a specific alteration
- status
- present
- gene
- DMMR
- alteration
- stated without a specific alteration
- status
- present
- prior therapy
- class
- following systemic therapy and not candidates for curative surgery or radiation
- status
- required
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for Lenvima (lenvatinib) (accelerated-approval table). Only dimensions stated in that wording are part of this definition.
- source wording
- In combination with pembrolizumab for advanced endometrial carcinoma not MSI-H or dMMR, with progression following systemic therapy and not candidates for curative surgery or radiation
Study evidence for this setting
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice